A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

Exclusion Criteria

• •Patients who have an active, known or suspected autoimmune disease
• •Patients must not have received prior IL-2 therapy
• •Prior treatment with an anti PD-1, anti PD-L1, or anti cytotoxic T lymphocyte associated protein 4 (anti CTLA-4) antibody, agents that target IL-2 pathway, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
• •Patients with hypertension must be on a stable antihypertensive regimen for the 14 days prior to Cycle 1 Day 1